Cosmo Pharmaceuticals N.V. (LON:0RGI)

Market Cap	1.75B +89.3%
Revenue (ttm)	156.24M -1.7%
Net Income	51.42M +1.7%
EPS	3.14 +0.1%
Shares Out	n/a
PE Ratio	34.08
Forward PE	431.47
Dividend	1.73 (1.51%)
Ex-Dividend Date	Jun 4, 2025

Volume	24,758
Average Volume	9,338
Open	116.00
Previous Close	115.40
Day's Range	115.20 - 116.70
52-Week Range	41.65 - 129.60
Beta	1.46
RSI	55.23
Earnings Date	Mar 9, 2026

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1997
• Employees: 332
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RGI

Financial Performance

Financial numbers in EUR